Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
147.32B
Market cap147.32B
Price-Earnings ratio
14.88
Price-Earnings ratio14.88
Dividend yield
6.74%
Dividend yield6.74%
Average volume
49.76M
Average volume49.76M
High today
$25.92
High today$25.92
Low today
$25.38
Low today$25.38
Open price
$25.48
Open price$25.48
Volume
47.26M
Volume47.26M
52 Week high
$27.69
52 Week high$27.69
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 147.32B, Pfizer(PFE) trades at $25.85. The stock has a price-to-earnings ratio of 14.88 and currently yields dividends of 6.7%.

On 2026-01-21, Pfizer(PFE) stock moved within a range of $25.38 to $25.92. With shares now at $25.85, the stock is trading +1.8% above its intraday low and -0.3% below the session's peak.

Trading volume for Pfizer(PFE) stock has reached 47.26M, versus its average volume of 49.76M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

PFE News

Simply Wall St 3h
The Bull Case For Pfizer Could Change Following Novavax Matrix-M Adjuvant Licensing Deal - Learn Why

In January 2026, Novavax announced a non-exclusive worldwide license and option agreement giving Pfizer access to its Matrix-M vaccine adjuvant technology for u...

The Bull Case For Pfizer Could Change Following Novavax Matrix-M Adjuvant Licensing Deal - Learn Why
Nasdaq 12h
Ex-Dividend Reminder: Albertsons Companies, Signet Jewelers and Pfizer

Looking at the universe of stocks we cover at Dividend Channel, on 1/23/26, Albertsons Companies Inc (Symbol: ACI), Signet Jewelers Ltd (Symbol: SIG), and Pfize...

Ex-Dividend Reminder: Albertsons Companies, Signet Jewelers and Pfizer
Simply Wall St 1d
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story

Pfizer (NYSE:PFE) has entered a non exclusive global licensing deal with Novavax for access to its Matrix M vaccine adjuvant technology. The agreement allows P...

Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story

Analyst ratings

57%

of 28 ratings
Buy
39.3%
Hold
57.1%
Sell
3.6%

More PFE News

Benzinga 2d
Novavax Shares Rise After Licensing Deal With Pfizer

Novavax, Inc. (NASDAQ:NVAX) shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer, Inc. (NYSE:PFE) for u...

Novavax Shares Rise After Licensing Deal With Pfizer
TipRanks 2d
GSK, Shionogi reach agreement with Pfizer for interest in ViiV Healthcare

GSK (GSK) and Shionogi & Co announced that they have reached agreement together with Pfizer (PFE) for the 11.7% economic interest in ViiV Healthcare Limited cur...

TipRanks 2d
Novavax enters license agreement with Pfizer for use of Matrix-M

Novavax (NVAX) has entered into a license agreement with Pfizer (PFE) for use of Novavax’s Matrix-M adjuvant. Under the terms of the agreement, Pfizer will obta...

The Motley Fool 2d
Down 55%, Should You Buy the Dip on Pfizer?

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard? Pfizer (PFE 0.93%) is in the Wall Street doghouse. I...

Down 55%, Should You Buy the Dip on Pfizer?
Nasdaq 3d
What to Expect From Pfizer's Non-Oncology Business in Q4?

Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on oncology sales, which generate more tha...

What to Expect From Pfizer's Non-Oncology Business in Q4?
Nasdaq 4d
Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,700 in Passive Income in 2026

Key Points These five stocks offer dividend yields of up to 9.4%. They represent different sectors, including communication services, energy, financials, heal...

Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,700 in Passive Income in 2026
The Motley Fool 5d
The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer and United Parcel Service

All three of these stocks sport dividend yields above 6%. If you're in the market for some no-brainer dividend stocks, I have some good and less-good news for...

The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer and United Parcel Service

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.